BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 1104 | Download: 1227
 |
Received |
|
2013-09-05 08:42 |
 |
Peer-Review Started |
|
2013-09-05 11:27 |
 |
To Make the First Decision |
|
2013-09-27 16:54 |
 |
Return for Revision |
|
2013-09-29 10:30 |
 |
Revised |
|
2013-10-08 22:16 |
 |
Second Decision |
|
2013-11-04 17:28 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-11-05 10:03 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-11-13 18:16 |
 |
Typeset the Manuscript |
|
2013-12-16 11:54 |
 |
Publish the Manuscript Online |
|
2014-01-20 16:41 |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Autobiography |
Article Title |
131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma
|
Manuscript Source |
Invited Manuscript |
All Author List |
Qing He, Wu-Sheng Lu, Yang Liu, Yong-Song Guan and An-Ren Kuang |
Funding Agency and Grant Number |
|
Corresponding Author |
Dr. An-Ren Kuang, Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan Province, China. kuanganren@263.net |
Key Words |
Hepatocellular carcinoma; 131I-metuximab; Transcatheter arterial chemoembolization; Radioimmunotherapy |
Core Tip |
131I-metuximab has high affinity with a target antigen highly expressed on hepatocellular carcinoma (HCC) cells and a limited area of action. The combination of metuximab and transcatheter arterial chemoembolization had a synergistic effect in the treatment of HCC. It may represent a promising treatment modality for patients with advanced HCC, especially for those patients with multiple nodules who have a heavy tumor burden. |
Publish Date |
2014-01-20 16:41 |
Citation |
He Q, Lu WS, Liu Y, Guan YS, Kuang AR. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 9104-9110 |
URL |
http://www.wjgnet.com/1007-9327/full/v19/i47/9104.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v19.i47.9104 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345